Who We Are

Rainer Fuchs

Executive Director ofbi³

Rainer is a molecular biologist by training, with a Ph.D. degree in Biochemistry and a Masters in Microbiology. He has been with Biogen Idec since 2000 in various executive leadership roles, including co-head of Discovery Research and VP Informatics and Operations. Before joining Biogen, Rainer was Global Head of Lead Generation Informatics for Aventis Pharma. His experience in the biopharmaceutical industry includes senior leadership positions at Ariad Pharmaceuticals and Glaxo Wellcome. Prior to industry, Rainer was staff scientist at the European Molecular Biology Laboratory (EMBL).

Jeffrey Behrens

Head of Business Operations forbi³

Jeff brings his entrepreneurial background tobi³. Previously, Jeff was the founder and CEO of The Telluride Group, inc., an IT services company with a strong biotech practice that was sold to mindSHIFT Technologies in late 2003. Jeff is an active angel investor and a member of the screening committee of Launchpad Ventures and MIT’s Venture Mentoring Service. Jeff also volunteers with several community organizations including the Museum of Science and Harvard Alumni Association and sits on the boards of Finale Restaurants and Marble and Granite, a mid-market importer and distributor of building materials. Jeff has an MBA from MIT’s Sloan School of Management and a Masters of Science from the Joint Harvard/MIT Division of Health Sciences and Technology.



About Biogen Idec

Biogen Idec (NASDAQ:BIIB) is one of the oldest biotechnology companies and a leader in biopharmaceuticals. Headquartered in Cambridge, MA, the company maintains research centers of excellence in San Diego, CA and Cambridge, MA. Over 20 products are currently in clinical development addressing a variety of high unmet medical needs. With patients in more than 90 countries, two blockbuster drugs lead Biogen Idec’s product lineup: RITUXAN® (rituximab) for the treatment of certain B-cell non-Hodgkin’s lymphomas (NHL) and rheumatoid arthritis, and AVONEX® (Interferon beta 1-a) for the treatment of patients with relapsing forms of multiple sclerosis (MS). TYSABRI® (natalizumab) was introduced to the U.S. market in 2006 as a monotherapy for relapsing forms of MS. In addition to Biogen Idec’s portfolio of drug candidates, the company’s capabilities and capacity for protein manufacturing are world-class in quality and scale.
Learn more about Biogen Idec .